Expertise in
44
conditions

Hanns Lochmuller

Central Parkway, 
Newcastle Upon Tyne, ENG, GB 
Expertise in
44
conditions
Central Parkway, 
Newcastle Upon Tyne, ENG, GB 

Overview

Hanns Lochmuller practices practicing medicine in Newcastle Upon Tyne, United Kingdom.

Mr. Lochmuller is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Congenital Myasthenic Syndrome, Paramyotonia Congenita, Myotonic Dystrophy Type 2, and Myotonic Dystrophy.

He is actively involved in clinical research, co-authoring 431 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Central Parkway, Newcastle Upon Tyne, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials
Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials
Enrollment Status: Completed
Publish Date: April 13, 2021
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Enrollment Status: Completed
Publish Date: April 27, 2018
View 5 Less Clinical Trials

430 Total Publications

Expanding Vamorolone Treatment Access for Canadians with Duchenne Muscular Dystrophy.
Expanding Vamorolone Treatment Access for Canadians with Duchenne Muscular Dystrophy.
Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: July 13, 2026

Frequently Asked Questions about Hanns Lochmuller

Is Hanns Lochmuller a top-rated expert for Congenital Myasthenic Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Hanns Lochmuller is classified as an Elite expert for Congenital Myasthenic Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hanns Lochmuller participate in research or clinical trials?

Yes. Hanns Lochmuller has published 430 articles and abstracts on conditions like Congenital Myasthenic Syndrome. You can view a list of Hanns Lochmuller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lochmuller's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 31 Advanced Conditions
View All 73 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile